Cronos Group (CRON) Expected to Announce Quarterly Earnings on Monday

Cronos Group (NASDAQ:CRON) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Cronos Group to post earnings of $0.01 per share and revenue of $42.21 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. Cronos Group had a negative return on equity of 1.12% and a negative net margin of 6.44%.The firm had revenue of $58.39 million for the quarter, compared to analysts’ expectations of $38.51 million.

Cronos Group Stock Performance

Shares of NASDAQ:CRON traded up $0.02 on Monday, hitting $2.66. The stock had a trading volume of 690,783 shares, compared to its average volume of 1,397,698. The company has a market capitalization of $999.00 million, a price-to-earnings ratio of -265.23 and a beta of 0.87. Cronos Group has a twelve month low of $1.81 and a twelve month high of $3.43. The firm’s 50 day moving average price is $2.59 and its 200-day moving average price is $2.60.

Institutional Trading of Cronos Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC grew its position in shares of Cronos Group by 10.4% during the 4th quarter. Virtu Financial LLC now owns 52,852 shares of the company’s stock worth $139,000 after purchasing an additional 4,990 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Cronos Group by 12.5% during the 4th quarter. Headlands Technologies LLC now owns 63,097 shares of the company’s stock valued at $166,000 after acquiring an additional 6,998 shares during the period. Federation des caisses Desjardins du Quebec grew its holdings in shares of Cronos Group by 169.7% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 16,371 shares of the company’s stock worth $42,000 after purchasing an additional 10,300 shares in the last quarter. Brooklyn Investment Group increased its position in shares of Cronos Group by 5,733.0% in the third quarter. Brooklyn Investment Group now owns 10,966 shares of the company’s stock worth $30,000 after purchasing an additional 10,778 shares during the period. Finally, Scientech Research LLC bought a new position in shares of Cronos Group in the third quarter worth $32,000. Institutional investors own 8.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on CRON shares. Sanford C. Bernstein reissued a “market perform” rating and issued a $2.30 target price on shares of Cronos Group in a report on Wednesday, January 14th. Weiss Ratings downgraded shares of Cronos Group from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. TD Securities started coverage on Cronos Group in a research note on Tuesday, February 24th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of Cronos Group from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Canaccord Genuity Group began coverage on Cronos Group in a research report on Tuesday, January 27th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $2.30.

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.